BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2458761)

  • 1. Comparison between complement and melittin hemolysis: anti-melittin antibodies inhibit complement lysis.
    Laine RO; Morgan BP; Esser AF
    Biochemistry; 1988 Jul; 27(14):5308-14. PubMed ID: 2458761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the discontinuous epitope in human complement protein C9 recognized by anti-melittin antibodies.
    Laine RO; Esser AF
    J Immunol; 1989 Jul; 143(2):553-7. PubMed ID: 2472443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
    Sims PJ
    Biochim Biophys Acta; 1983 Aug; 732(3):541-52. PubMed ID: 6871214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL; Monahan JB; Brickner A; Sodetz JM
    Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
    Kontermann R; Deppisch R; Rauterberg EW
    Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
    Zalman LS; Müller-Eberhard H
    Mol Immunol; 1994 Mar; 31(4):301-5. PubMed ID: 8139583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J; Gold D; LoVerde PT; Fishelson Z
    Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
    Houle JJ; Hoffmann EM; Esser AF
    Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T; Meri S
    J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
    Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
    Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
    Rosenfeld SI; Packman CH; Leddy JP
    J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking antibodies specific for human albumin interfere with the hemolytic activity of the membrane attack complex of complement.
    Houle JJ; Hoffmann EM
    Biochem Biophys Res Commun; 1994 Apr; 200(1):135-41. PubMed ID: 8166680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the association of the eighth and ninth components of human complement within the membrane-bound cytolytic complex.
    Monahan JB; Stewart JL; Sodetz JM
    J Biol Chem; 1983 Apr; 258(8):5056-62. PubMed ID: 6833292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
    Schönermark S; Filsinger S; Berger B; Hänsch GM
    Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluid-phase assembly of the membrane attack complex of complement.
    Silversmith RE; Nelsestuen GL
    Biochemistry; 1986 Feb; 25(4):841-51. PubMed ID: 3964648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.